Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.7090
-0.0370 (-4.96%)
Mar 31, 2025, 2:20 PM EDT - Market open
Xilio Therapeutics Revenue
In the year 2024, Xilio Therapeutics had annual revenue of $6.34M. Xilio Therapeutics had revenue of $1.72M in the quarter ending December 31, 2024.
Revenue (ttm)
$6.34M
Revenue Growth
n/a
P/S Ratio
6.29
Revenue / Employee
$99,125
Employees
64
Market Cap
36.71M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
XLO News
- 20 days ago - Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 6 weeks ago - Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? - Benzinga
- 6 weeks ago - Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs - GlobeNewsWire
- 6 weeks ago - AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies - GlobeNewsWire
- 7 weeks ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - GlobeNewsWire
- 2 months ago - Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire